drugset / Trial / NCT00404885

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404885

Phase 3 Completed 108 enrolled Lux Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Timeline

Start
2007-01
Primary completion
2008-11
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Voclosporin Other / unclassified 0.2 mg/kg Oral
Comparator Voclosporin Other / unclassified 0.4 mg/kg Oral
Comparator Voclosporin Other / unclassified 0.6 mg/kg Oral